About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

THR-149 dose level 3

Company: ThromboGenics
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Completed NCT NCT03511898

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

Not yet reported ThromboGenics 12 participants Est. completion 2019-05-22 7 sites Stand-alone

Other conditions: Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
View official trial listing →
Completed NCT NCT04527107

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Not yet reported Oxurion 135 participants Est. completion 2023-11-22 78 sites Stand-alone

Other conditions: Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT03511898

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.